test

Developmental Therapeutics 

Nikolai Alexandrovich Podoltsev MD, PhD

Assistant Professor of Medicine (Hematology); Associate Director of the Hematology/Oncology Fellowship Program

Clinical Interests

myeloprolipherative neoplasms (MPN); myelodysplastic syndromes (MDS); acute leukemias


Board Certifications

2010
Hematology, Internal Medicine, Board Certified
2000
Internal Medicine, Board Certified
2010
Medical Oncology, Board Certified

Patient Care Locations

 
nikolai_podoltsevfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Leukemia, not otherwise specified and Myeloid and Monocytic Leukemia A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Antiphospholipid Syndrome (APS) Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, not otherwise specified and Myeloid and Monocytic Leukemia An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults

More Clinical Trials...

Edit Profile